Published in AIDS Weekly, December 13th, 1999
Further, one-third of individuals with HIV and underlying liver disease have discontinued highly active antiretroviral therapy (HAART) because of its potential toxicity to the liver. Information on the topic was presented at the 37th Annual Meeting of the Infectious Diseases Society of America (IDSA), held November 18-21, 1999, in Philadelphia, Pennsylvania.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.